%0 Journal Article
%T Defining the subset of the patients in whom ¡° Less is More ¡± for hormone receptor-positive breast cancer: clinical risk  vs . genomics risk
%A Yeon Hee Park
%J SCIE-indexed Journal
%D 2017
%R 10.21037/12032
%X Omitting adjuvant chemotherapy by risk assessments using clinical and genomic signature is a very important topic for patients and clinician because chemotherapy has potentials to be harmful with various reasons. Currently, NCCN recommend to consider 21-gene RT-PCR assay (1) for patients with hormone receptor-positive breast cancer who have tumor beyond 0.5 cm after curative surgery (2). However, this clinical application of multi-gene assay is not enough to be useful with category 2A level of evidence. In addition, high price of the test is preventing it from becoming widely available
%U http://tcr.amegroups.com/article/view/12032/html